Genomic Vision presented the positive interim results of the HNPCC test at the 2014 ESHG congress in Milan

Regulatory News:

Genomic Vision (Paris:GV) (FR0011799907 – GV / PEA-PME eligible), a molecular diagnosis company that specializes in the development of diagnostic tests for genetic diseases and cancers, today announces that the interim results of its program to develop a test for diagnosing hereditary nonpolyposis colorectal cancer (HNPCC, or Lynch Syndrome) were presented at the ESHG (European Society of Human Genetics) annual congress held in Milan, Italy, from May 31 to June 3, 2014.

The test currently being developed by Genomic Vision is aimed at detecting a genetic predisposition to HNPCC through an analysis of certain DNA mismatch repair genes (MSH2, MLH1, MSH6 and PMS2) by molecular combing. People carrying a mutation in one of these genes have an 80% risk of developing colon cancer.

The interim results presented at the congress show that an analysis of these genes by molecular combing is effective in detecting major rearrangements, in just a single trial. Indeed, Genomic Vision’s proprietary technology was able to detect deletions of 1 or more exons (of 4 kb to 53 kb in size) in one of these genes or an inversion in the MSH2 gene.

These results were obtained in collaboration with Dr Juul Wijnen’s team from the Human and Clinical Genetics department at LUMC (Leiden University Medical Center), in the Netherlands.

Aaron Bensimon, Genomic Vision’s co-founder and Chairman, says: "I would like to thank the entire team of clinical investigators participating in this study. The interim results presented in Milan give us great confidence in its continuation, and our objective of marketing the HNPCC test based on molecular combing technology in 2015 remains unaltered.”

ABOUT GENOMIC VISION

A spinoff of the Institut Pasteur, Genomic Vision is a molecular diagnostics company specialized in developing diagnostic tests for genetic diseases and cancers. Using "molecular combing”, an innovative technology that allows the direct visualization of individual DNA molecules, Genomic Vision detects quantitative and qualitative variations in the genome that are at the origin of numerous serious pathologies. Having benefited from the financial support of the Institut Pasteur, SGAM AI, Vesalius Biocapital and Quest Diagnostics, the Company is developing a solid portfolio of tests that notably target breast cancer and cancer of the colon. Since 2013, the Company has marketed the CombHeliX FSHD test for identifying a myopathy that is difficult to detect, Facio-scapulo-humeral dystrophy (FSHD), in the United States thanks to a strategic alliance with Quest Diagnostics, the American leader in diagnostic laboratory tests, and in France.

ABOUT MOLECULAR COMBING

DNA molecular combing technology considerably improves the structural and functional analysis of DNA molecules. DNA fibers are stretched out on glass slides, as if "combed”, and uniformly aligned over the whole surface. It is then possible to identify genetic anomalies by locating genes or specific sequences in a patient’s genome using genetic markers, an approach developed by Genomic Vision and patented under the name Genomic Morse Code. This exploration of the entire genome at high resolution via a simple analysis enables the direct visualization of genetic anomalies that are undetectable by other technologies.

For further information, please go to www.genomicvision.com

DISCLAIMER

This press release contains certain forward-looking statements concerning Genomic Vision and its business. Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the prospectus on which the French Financial Market Authority (AMF) granted its visa n° 14-087 on March 19, 2014 and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.

This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Genomic Vision shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.